Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Characterization of Interactions Among CYP1A2, CYP2B4, and NADPH-cytochrome P450 Reductase: Identification of Specific Protein Complexes

J. Patrick Connick, James R. Reed and Wayne L. Backes
Drug Metabolism and Disposition March 2018, 46 (3) 197-203; DOI: https://doi.org/10.1124/dmd.117.078642
J. Patrick Connick
Department of Pharmacology and Experimental Therapeutics and Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, Louisiana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James R. Reed
Department of Pharmacology and Experimental Therapeutics and Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, Louisiana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wayne L. Backes
Department of Pharmacology and Experimental Therapeutics and Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, Louisiana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Article Figures & Data

Figures

  • Additional Files
  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Detection of physical complexes between CYP1A2 and CYP2B4 using BRET. (A) Physical complex formation between CYP2B4 and CYP1A2. pGFP2-N1/CYP2B4-GFP and pRluc-N2/CYP1A2-Rluc were transfected into HEK-293T/17 cells at different ratios and BRET was measured. (B) Effect of POR on the CYP1A2/CYP2B4 BRET pair. pGFP2-N1/CYP1A2-GFP and pRluc-N2/CYP2B4-Rluc were cotransfected into HEK-293T/17 cells (blue). This was repeated in the presence of cotransfected unlabeled POR, which did not measurably affect BRETmax (red), indicating that the CYP1A2-CYP2B4 complex is stable in the presence of POR. The mean ± S.D. value for triplicate determinations is represented unless the error bars are smaller than the plotted points.

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    Effect of unlabeled CYP1A2 on the POR/CYP2B4 BRET pair. pGFP2-N1/CYP2B4-GFP and pRluc-N1/POR-Rluc were cotransfected into HEK-293T/17 cells at varying GFP:Rluc ratios both in the absence (blue) and presence (red) of cotransfected, unlabeled CYP1A2. Each point represents the mean of triplicate determinations with the S.D. value within the data point.

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    Effect of unlabeled CYP2B4 on the BRET-sensitive POR-CYP1A2 complex. pGFP2-N1/CYP1A2-GFP and pRluc-N1/POR-Rluc were cotransfected into HEK-293T/17 cells at varying GFP:Rluc ratios in the absence (blue) and presence (red) of cotransfected unlabeled CYP2B4. Points represent the mean ± S.D. values for three measurements; for most points, the error is smaller than the data point.

  • Fig. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    Effect of cotransfection of CYP1A2-GFP and CYP2B4-GFP on PROD and EROD in microsomes isolated from transfected HEK-293T/17 cells. Cells were transfected with pGFP2-N1/CYP1A2-GFP, pGFP2-N1/CYP2B4-GFP, or both. Microsomes derived from these cells were then incubated in the presence of either 7-pentoxyresorufin or 7-ethoxyresorufin, and the initial rate of resorufin accumulation was determined spectrofluorometrically. The experimentally determined rates were then compared with those predicted for CYP1A2 and CYP2B4 if they behaved as monomers that simply competed for the available POR. Because each group of transfected cells contained different levels of POR, CYP1A2, and CYP2B4, the predicted rates were determined using Dynafit 4, based on the model described in Supplemental Fig. 1. Consequently, if the P450 enzymes affected each other’s function, the experimental data would be expected to deviate from the “predicted” activities. This analysis showed that cotransfection of both P450s led to lower rates of PROD activity (A) and higher rates of EROD activity (B) than predicted by simple competition. Protein concentrations from the CYP1A2 group were 0.048 and 0.005 μM for CYP1A2 and POR, respectively. Concentrations for the CYP2B4 group were 0.040 and 0.005 μM for CYP2B4 and POR, respectively. Concentrations for the group cotransfected with both CYP1A2 and CYP2B4 were 0.051, 0.045, and 0.005 μM for CYP1A2, CYP2B4, and POR, respectively. The activities represent the mean ± S.E.M. values for four replicates. Unpaired t test: *P < 0.05; ***P < 0.001 for the difference between the measured and predicted values.

  • Fig. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 5.

    Effect of unlabeled POR on the BRET signal for the CYP1A2-CYP1A2 complex. pGFP2-N1/CYP1A2-GFP and pRluc-N2/CYP1A2-Rluc were cotransfected into HEK-293T/17 cells, and BRET was measured (blue curve). This was repeated in the presence of cotransfected unlabeled POR (red curve). The decrease in BRETmax is consistent with disruption of the CYP1A2-CYP1A2 complex. Each point represents the mean value of triplicate determinations with the S.D. value within the data points.

  • Fig. 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 6.

    Effect of unlabeled CYP2B4 on the BRET signal for the CYP2B4-CYP2B4 BRET pair. pGFP2-N1/CYP2B4-GFP and pRluc-N2/CYP2B4-Rluc were cotransfected into HEK-293T/17 cells, and BRET was measured in the presence and absence of different amounts of cotransfected unlabeled CYP2B4. The presence of unlabeled competitor did not have an effect on the BRETmax, suggesting that CYP2B4-GFP and CYP2B4-Rluc do not form a specific BRET-detectible complex. Each point represents the mean value of triplicate determinations with the S.D. value within the data points.

Additional Files

  • Figures
  • Data Supplement

    • Supplemental Data -

      Supplemental Table 1 – Information on the GFP, Rluc, and WT P450 System Protein Constructs
      Supplemental Figure 1 – Dynafit 4 script used to predict both 7-ethoxyresorufin-Odealkylation (EROD) and 7-pentoxyresorufin-O-dealkylation (PROD) when CYP1A2 and CYP2B4 exist as functional monomers that simply compete for limiting concentrations of NADPH-cytochrome P450 reductase (CPR)

PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 46 (3)
Drug Metabolism and Disposition
Vol. 46, Issue 3
1 Mar 2018
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Characterization of Interactions Among CYP1A2, CYP2B4, and NADPH-cytochrome P450 Reductase: Identification of Specific Protein Complexes
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Specific Complexes among CYP1A2, CYP2B4, and P450 Reductase

J. Patrick Connick, James R. Reed and Wayne L. Backes
Drug Metabolism and Disposition March 1, 2018, 46 (3) 197-203; DOI: https://doi.org/10.1124/dmd.117.078642

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

Specific Complexes among CYP1A2, CYP2B4, and P450 Reductase

J. Patrick Connick, James R. Reed and Wayne L. Backes
Drug Metabolism and Disposition March 1, 2018, 46 (3) 197-203; DOI: https://doi.org/10.1124/dmd.117.078642
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Humanized PXR-CAR-CYP3A4/7 Mouse as Model of Induction
  • Ozanimod Human Metabolism and Disposition
  • High-Throughput Characterization of SLCO1B1 VUS
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics